Rivaroxaban works by selectively inhibiting Factor Xa, an essential component in the blood coagulation cascade. By blocking this factor, the drug effectively prevents the conversion of prothrombin to thrombin, which is necessary for fibrin clot formation. This action reduces the risk of clot development, making it a valuable therapeutic in managing thrombosis-related disorders.
